News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Top Scientist Plans Major Changes for Drug Research


9/11/2013 7:32:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck & Co. (MRK)’s new top scientist is planning major changes for the second-largest U.S. drugmaker, including cutting dead-end research projects and focusing its laboratories on biotechnology and cancer medicines. Roger Perlmutter, Merck’s research and development chief, outlined his plans at a dinner with analysts yesterday at the Capital Grille steakhouse in downtown Manhattan. He replaced the company’s previous research chief, Peter Kim, in April. Perlmutter “told the R&D organization that ‘this is going to be major surgery’ that ‘will take time to recover,’ but bring forth a stronger organization,” Seamus Fernandez, an analyst with Leerink Swann & Co. who was at the dinner, said in a note to clients.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES